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Background: Appropriate treatment of acute hepatitis C is still a matter of controversy due to the lack of large
controlled trials.
Aim: To assess the effectiveness of interferon as treatment for acute hepatitis C by meta-analysis.
Methods: MEDLINE search (1985–2002) was supplemented with manual searches of reference lists. Studies were
included if they were controlled trials comparing interferon to no treatment and if they included patients with either
post-transfusion or sporadic acute hepatitis C. Twelve trials were analyzed (414 patients). The outcome assessed was the
sustained virological response (SVR) rate (undetectable hepatitis C virus RNA in serum at least 6 months after
cessation of therapy).
Results: Interferon significantly increased the SVR (risk difference 49%; 95% confidence interval 32.9–65%) in
comparison to no treatment. The risk difference of SVR increased from 5 to 90% when trials were ordered by
increasing interferon weekly dose. Delaying therapy by 8–12 weeks after the onset of disease does not compromise the
SVR rate.
Conclusions: Current evidence is sufficient to recommend interferon treatment of patients with acute hepatitis C. A
later initiation of therapy yields the same likelihood of response as early treatment. A daily induction dose during the
1st month is the best option of treatment.
q 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Keywords: Acute hepatitis C; Interferon; Sustained virological response
1. Introduction
Over the last 5 years three different meta-analyzes of
controlled trials of standard interferon (IFN) as treatment for
acute hepatitis C have shown that treating patients with a
low dose of standard IFN (3 megaunits [MU] thrice a week)
for a short course (12 weeks) is significantly more effective
than no treatment in obtaining sustained virological
response [1–3]. The substantial overrepresentation of
post-transfusion acute hepatitis C in these meta-analyzes
(the majority of patients included in the published studies
had acquired infection via contaminated blood products)
potentially limits their generalizability. Currently, the
incidence of post-transfusion acute hepatitis C has fallen
markedly, and most cases seen in current practice are
acquired by intravenous drug abuse or by non-parenteral
and undefined ways [4].
Since the previous meta-analyzes were reported, both a
number of uncontrolled studies and an increasing number of
controlled trials have been published. However, the results of
both controlled and uncontrolled trials remain inconsistent and
the overall assessment of treatment effect is difficult to
evaluate. In particular, the main limitations of these studies
are the small sample size and the high heterogeneity of the
enrolled patients due to the asymptomatic course of the disease.
In 2002 the National Institute of Health (NIH) Consensus
Conference on the Management of Hepatitis C stated that
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the minimum dose required for patients with acute hepatitis
C in order to obtain a significant benefit is 3 MU of a-IFN
given three times weekly (TIW) for at least 12 weeks [5].
Although the final statement from the NIH was that
treatment of patients with acute hepatitis C is warranted,
available data are not sufficient to answer two unresolved
issues: when therapy should be started and how patients
should be treated [5].
In order to overcome some of the limitations mentioned
above as well as increase the relevance of the statistical
analysis we performed a meta-analysis of controlled trials
on treatment of acute hepatitis C with IFN monotherapy.
Our aim was to define the optimal treatment schedule as
well as the best time to begin treatment in order to avoid
chronic hepatitis C virus (HCV) infection.
2. Materials and methods
2.1. Search strategy and inclusion criteria
The primary source of the studies reviewed was the MEDLINE
database (1985–2002), limited to English language literature. The medical
subject headings used were acute hepatitis non-A, non-B; acute hepatitis C;
interferon; randomized and clinical trials. Reference lists of available
review articles and primary studies were also checked to identify other
studies not found in the computerized search. Furthermore, we searched the
abstracts of the American Association for the Study of the Liver Diseases
(1995–2002) and of the European Association for the Study of the Liver
(1995–2002).
The potentially relevant papers were initially classified into two subsets.
Subset 1 included a total of 12 cohort studies [6–17] that reported data on
serum HCV-RNA clearance. The cohort studies of subset 1 were reviewed
to assess the overall likelihood of sustained virological response in treated
patients [6–8,10,12,13,15–17] and the likelihood of spontaneous HCV
RNA clearance in untreated controls [9,11,14], by the Confidence Profile
Method using the Fast*Pro software [18–20].
Studies of subset 2 were included in the meta-analysis if they were
randomized or non-randomized controlled trials (RCTs and NRCTs),
comparing different schedules of standard interferon monotherapy with or
without an untreated control group; if they had been published in English as
full length papers or abstracts; if they included adult patients with a
diagnosis of acute hepatitis C, either post-transfusion or sporadic. Ten of
the 26 potentially relevant papers were excluded because the results were
published as preliminary reports [21–23] or as abstracts [24–30] before the
final article was published. After these ten studies were excluded, 16
controlled trials [31–46], 12 published as a full article [31,33–39,
42–44,46] and four as abstracts [32,40,41,45] remained in the meta-
analysis.
2.2. Data extraction and outcomes
The trials were first reviewed using a list of predefined, pertinent issues
that concerned the characteristics of patients and treatments. Extraction of
the data was independently performed by two readers (A.L. and D.D.B.)
who compared results and agreed on a consensus.
The following minimal criteria for the diagnosis of acute hepatitis C
were present in all studies: (1) increase of ALT level at least 2.5 times
above normal, on two separate occasions at least 2 weeks apart; (2)
serological exclusion of HAV, HBV, EBV, CMV and HSV; and (3) reliable
exclusion of non-viral causes of hepatitis (i.e. hepatotoxins or severe right
sided heart failure or autoimmune hepatitis). Exclusion of subjects with pre-
existing chronic hepatitis C and/or chronic liver disease was explicitly
mentioned in all studies, based on history, physical examinations and
biochemistry. In most studies the diagnosis of acute hepatitis C was based
on the detection of HCV RNA [31,33–37,39–42,45] in the first serum
sample and in five of these [33,36,37,40,42] was confirmed by subsequent
seroconvertion from negative to positive anti-HCV, according to
international criteria [47].
2.3. Statistical analysis
The outcome assumed as measure of IFN efficacy was the percentage of
patients with negative serum HCV RNA after post-treatment follow-up
(sustained virological response). The evaluation of therapeutic effective-
ness was performed by an intention-to-treat method. When not reported in
the trial, the response rate according to intention-to-treat was calculated. In
order to combine results from individual trials, we used the proportion of
sustained virological responders observed in the treatment and control
groups. With these observed proportions of response, the risk differences
(RD) were computed for each trial. We calculated the overall RD among
the frequencies of the events in both treated and control groups, according
to the DerSimonian and Laird random-effects model [48]. In addition to
within-study variance, the random-effects model considers heterogeneity
among studies. The 95% confidence interval (95% CI) of the RD was also
calculated. The number of patients needing treatment (NNT) to obtain one
sustained virological response, deriving from the inverse of the risk
difference, was also used as a measure of treatment effect [49]. We choose
to present the random effect model because we believe that the relevant
variation in treatment effects is a consequence of several inter-trial
differences.
Since several studies utilized a non-randomized design, we performed
the meta-analysis carefully considering the biases that may result because
of the lack of randomization [50]. A recommended approach to deal with
heterogeneity is sorting the heterogeneous group of studies into subgroups,
according to a stratifying variable suspected of causing the inconsistency.
We used eleven stratifying variables (RCTs vs. NRCTs, source of infection,
studies including patients with baseline ALT$8/,8 upper limit of normal,
Europeans vs. Orientals, percentage of HCV RNA clearance in untreated
patients below/above 15%, long vs. short duration of follow-up, full papers
vs. abstracts, high/low dose/week during the 1st month of treatment,
starting therapy before/after 60 days, all studies without trials reporting the
highest and the lowest therapeutic benefit, studies performed before/after
1995). Finally, we in turn excluded each study to ensure that no study alone
would be responsible for the significance of any result (the so-called robust
analysis). All our analyzes were computed using a software program.
3. Results
3.1. Cohort studies
To evaluate the effectiveness of interferon treatment on
subjects with acute hepatitis C enrolled outside controlled
trials, 12 cohort studies [6–17] reporting data on serum HCV
RNA clearance of 162 treated [6–8,10,12,13,15–17] and 81
untreated [9,11,14] patients, followed for a mean follow-up
of 20 months (range 2–60 months) were analyzed. A total of
243 subjects (25 post-transfusion, 218 sporadic cases) were
included. A large variability in interferon schedule was found
both in dose (ranging from 3 to 5–6 MU) and in length of
treatment (ranging from 4 to 52 weeks).
The overall likelihood of sustained virological response
was 70.5% (95% CI 62.6–78.3) for the 162 treated patients,
whereas the overall likelihood of achieving a spontaneous
serum HCV RNA clearance was 35.3% (95% CI 26.2–44.9)
for the 81 untreated controls.
3.2. Meta-analysis
The main features of the sixteen trials included in
the analysis are shown in Table 1 [31–46]. A total of
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640 patients (403 post-transfusion and 237 sporadic cases)
were included. Of these 640 patients, 320 were treated and
320 were untreated. The number of patients enrolled in each
trial varied greatly, ranging from 14 [36] to 90 [34]. Eight
studies were RCTs [25,31–37] and eight were NRCTs
[38–45]. We included in the meta-analysis the study of
Takano [34], in which six different regimens of IFN were
compared, considering the two groups of patients treated
with a very low dose of IFN (0.3 MU of IFN-b for 28 or 56
days) as a control group. In fact the rate of response in these
two control groups was 21%, which is consistent with the
control rate of all other studies. Furthermore in the study by
Gursoy [39], two different treatment groups (3 and
6–10 MU) were compared with the same control group.
In this trial we performed a comparison with each individual
interferon arm and each control group, separately. Finally,
in the small trial by Fabris [36], a daily dose of 3 MU of
interferon was compared to the same dose administered
three times weekly. We combined the results of the two
treatment arms of this trial and made a single pairwise
comparison with the overall weighted control rate of all the
remaining trials.
The criteria for inclusion were uniform in all, but three
trials, which included only patients with ALT levels above 8
[39] 10 [42] and 20 [46] times the normal limit. In four trials
most patients were jaundiced [40,42,44,46]. HCV RNA was
detected in serum by different homemade or commercial
polymerase chain reactions.
A large variability in IFN schedule was found either in
the individual dose, ranging between 3 MU [31–33,35–39,
43,44,46] and 6 MU [34,40–42,45] or in the length of
treatment, ranging between 4 [31,34,43] and 24 weeks
[41,42,45]. Patients began treated at different time points
from the onset of the disease, ranging from 15 [37] to 89
[42] days. The mean length of post-treatment follow up was
16 months, ranging from 6 [34,36,42] to 36 [31] months.
Table 1
Patients characteristics, therapeutic regimens and outcome of each trials included in the meta-analysis
Study (year of
publication)
Type of
study
Male
(%)
Mean
age
(years)
Modality of
infection
(% of sporadic)
Interferon regimens Dose/week
during the 1st
month (MU)
Follow-up
(months)
Sustained
virological
response n (%)
1 Omata 1991 RCT 36 39 28 b, 3 MU TIW i.v. for 4 weeks 9 36 T 7/11 (63.3)
C 1/14 (7.1)
2 Ohnishi 1991 NRCT 60 46 Posttransfusion b, 3 MU TIW i.v. for 4 weeks 9 24 NR
3 Viladomiu 1992 RCT 60 52 Posttransfusion a-2b, 3 MU TIW s.c. for 12 weeks 9 12 NR
4 Tassopulos 1993 NRCT 30 48 54 a-2b, 3 MU TIW s.c. for 6 weeks 9 12 NR
5 Li 1993 RCT 22 45 56 a-2b, 3 MU TIW s.c. for 12 weeks 9 12 NR
6 Alberti 1993 NRCT NR 45 29 a-2a, 6 MU TIW s.c. for 16–24 weeks 18 18 T 8/11 (72.7)
C 2/10 (20)
7 Palmovic 1994 NRCT NR NR Posttransfusion a-r, 3 MU TIW for 24 weeks 9 12 NR
8 Takano 1994 RCT 53 47 29 b, 0.3–6 MU daily i.v. for 4–8 weeks Na 6 T 32/59 (54.2)
C 11/31 (35.5)
9 Hwang 1994 RCT 75 54 Posttransfusion a-2b, 3 MU TIW s.c. for 12 weeks 9 12 T 9/16 (56.2)
C 6/16 (37.5)
10 Lampertico 1994 RCT 14 46 Posttransfusion a-2b, 3 MU TIW i.m. for 12 weeks 9 18 T 13/22 (59.1)
C 6/16 (37.5)
11 Calleri 1998 RCT 85 29 95 b, 3 MU TIW i.m. for 12 weeks 9 22 T 5/20 (25)
C 4/20 (20)
12 Delawaide 1999 NRCT NR NR 100 a-2b, 5 MU daily s.c. for 8 weeks 35 24 T 11/13 (84.6)
C 3/16 (18.7)
13 Storozhakov 1999 NRCT NR NR NR a 2b, 6 MU TIW s.c. for 18 weeks 18 18 T 7/13 (53.8)
C 2/12 (16.6)
14a Gursoy 1 2001 NRCT 56 38 53 a-2b, 3 MU TIW s.c. for 12 weeks 9 18 T 6/16 (37.5)
C 1/17 (5.8)
14b Gursoy 2 2001 NRCT 56 38 54 a-2b, 6 MU TIW s.c. for 12 weeks 18 18 T 13/20 (65)
C 1/17 (5.8)
15 Jaeckel 2001 NRCT 43 36 100 a-2b, 5 MU daily sc for 4 weeks,
then 5 MU TIW s.c. for 20 weeks
35 6 T 3/44 (97.7)
C 28/40 (70)
16 Fabris 2001 RCT 71 32 NR a-2a, 3 MU daily TIW s.c for 36 days
or 3 MU TIW s.c. for 12 weeks
9 6 T 2/6 (33.3)
21 T 3/8 (37.5)
RCT, randomized controlled trials; NRCT, non-randomized controlled trial; NR, not reported; i.v., intravenously; s.c., subcutaneously; i.m.,
intramusculary; MU, mega units; TIW, three times weekly; T, treated; and C, controls.
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Nine studies reported the incidence of side effects
[33,37–40,42–44,46]. Compliance and overall tolerance
of IFN was good. Treated patients experienced side effects
as in chronic hepatitis C. No discontinuation of therapy was
reported in all trials. IFN was well tolerated also in
jaundiced patients [40,42,44,46].
The rate of serum HCV RNA clearance after post-
treatment follow-up was reported in 12 studies [31,33–37,
39–42,45]. The benefit of IFN on sustained virological
response is shown in Fig. 1. IFN significantly increased viral
clearance in all, but two trial [36,37]. The highest therapeutic
benefit of IFN was observed in the RCT by Omata [31] which
is the earliest trial. The pooled estimate of the treatment effect
was significant (Risk Difference 49%, 95% CI 33–65,
P , 0:00001) (NNT ¼ 2). In all the robust analyzes the
pooled estimate of the treatment effect was significant.
The magnitude of treatment effect was different among
studies. It is possible that this reflects differences in the
schedules of treatment. To identify the optimal treatment
schedules we performed a meta-analysis of ten trials
arranged by increasing weekly dose of IFN administered
during the 1st month (Fig. 2). Two trials [31,34] were not
included because of the lack of data. The risk difference of
sustained virological response increased from 5 to 90%
when trials were ordered by increasing weekly dose,
suggesting that an induction with a daily induction dose of
IFN is the best schedule of treatment.
We found a remarkable heterogeneity among the studies.
We performed subgroup analyzes to evaluate whether there
was a different effect of treatment in predefined subgroups of
trials. Subgroup analyzes were carried out in relation to
patients and study characteristics (Table 2). Analysis by rate
of HCV RNA clearance in untreated patients below/above
15% showed that the pooled risk difference was 64.5% (95%
CI 52.9–76) in studies with a control rate.15%, and 40.1%
(95% CI 18.6–61.5%) in studies with a control rate ,15%.
Analysis by induction schedule showed that the pooled risk
difference was 66.6% (95% CI 54.4–78.8) in studies
with high weekly dose of interferon and 29.9% (95% CI
16.4–43.3) in those with a low weekly dose of interferon.
Analysis by interval from disease onset to therapy showed
that the pooled risk difference was 49.9% (95% CI 7.6–93.3)
in patients starting treatment within 60 days from disease
onset and 45.4% (95% CI 25.4–65.4) in those who received
treatment after 60 days from disease onset.
4. Discussion
This meta-analysis of data from 12 controlled trials
shows that in acute hepatitis C standard interferon
monotherapy significantly improves sustained virological
response in comparison to no treatment. The benefit on
HCV RNA clearance is large (NNT ¼ 2) and clinically
relevant, supporting the decision to treat all patients. It is
noteworthy that the same effectiveness was observed in
patients in patients enrolled in cohort studies, thus
confirming the generalizability of the results obtained in
this meta-analysis. Overall, safety in all trials was good, and
jaundiced or symptomatic affected-patients did not show
any severe side effect. Delaying therapy by 60 days after the
onset of symptoms did not reduce the efficacy of treatment.
A daily induction dose of standard IFN appears to be highly
effective.
Fig. 1. Meta-analysis of 12 controlled trials [31,33–37,39–42,45] of standard interferon treatment for acute hepatitis C using random-effects model
with sustained virological response as endpoint. Risk difference and 95% CI for each study and the pooled estimate of the treatment effect with its
Confidence Interval are plotted on the graph. Studies are arranged chronologically based on the year of publication. MU, megaunits. Underlined
studies are RCTs.
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Many studies have tried to identify the ideal dose of
therapy, as well as factors that would increase the cost-
effectiveness of treatment in the individual patient. Since
data from controlled trials are still equivocal, the last
Consensus Development Conference on hepatitis C did not
recommend any regimen of treatment for acute hepatitis C
[5]. In the trial by Jaeckel, a regimen of five megaunits of
IFN daily for 4 weeks, followed by 5 MU of IFN TIW for
20 weeks achieved a sustained virological response in
almost all patients [42]. Similar results were obtained in the
study by Delwaide [40], in which a high induction dose was
administered. Our meta-analysis provides evidence that
treatment with a daily induction dose of standard interferon
is the best option for sustained virological response. We
believe the available information is inadequate in determin-
ing the optimal length of treatment.
Although some authors have suggested that the benefit of
interferon monotherapy may be higher in patients infected
with HCV genotype other than 1 [6,45] or in patients with
low pre-treatment HCV RNA levels [6,33,34], other authors
could not confirm these observations [39,40,42,51]. There-
fore, a level of accuracy sufficient to predict interferon
responsiveness in the individual patient cannot be reached.
We observed that the benefit of interferon treatment was
higher in the subgroup of trials including symptomatic
patients. However, this summary results describe only
between-study, not between-patients, variation because they
reflect group averages rather than individual data. Thus,
caution must be exercised when interpreting results from
exploratory analysis.
In this meta-analysis the overall rate of chronicity in
untreated patients was very high (ranging from 85% in
controlled and 65% in uncontrolled studies), providing a
strong rationale for antiviral therapy during the acute phase
of the disease. The natural course of acute hepatitis C is
poorly defined because the available studies are of small
size and are heterogeneous. The small sample size is
justified because it is difficult to enrol patients at diagnosis,
either for the lack of an accepted serologic definition of
acute hepatitis C or because the disease is often asympto-
matic, with normal or minimally elevated serum ALT
levels, and rarely recognized outside of surveillance
programs. Therefore, the best method for detecting an
acute HCV infection is to screen high-risk patients for
seroconversion from a past negative to a positive test [52].
The key clinical question is whether all patients with
acute hepatitis C should immediately receive treatment or
whether IFN therapy can be delayed and administered
only to the subgroup of patients who might become
chronically infected. Santantonio et al. [53], in a
prospective long-term study, observed that the chronicity
rate was higher in asymptomatic than in symptomatic
hepatitis. This prospective study clearly demonstrated
that a spontaneous HCV RNA clearance occurs within
8–12 weeks from the onset of the disease. The reported
value for spontaneous viral clearance is in keeping with
the results of the recently published study by Gerlach
[54], showing that patients with acute hepatitis C clear
the virus within the first 12 weeks. Finally, Hofer et al.
[55] in a small prospective study confirmed that patients
with acute icteric hepatitis C have a high rate of
spontaneous viral clearance within the 1st month after
the onset of symptoms. Moreover, this study showed that
viral load declined fast and continuously in symptomatic
Fig. 2. Meta-analysis of ten controlled trials [33,35–37,39–42,45] of standard interferon treatment for acute hepatitis C using random-effects model
with sustained virological response, as end point. Risk difference and 95% CI for each study and the pooled estimate of the treatment effect with its
Confidence Interval are plotted on the graph. Studies are arranged based on increasing of weekly dose of IFN administered in the 1st month. MU,
megaunits. Underlined studies are RCTs.
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patients who cleared HCV spontaneously. However,
repeated viral load determinations may be not practical
in most clinical settings. Drawing firm conclusions based
on the results of these uncontrolled studies is hampered
by the small sample size and by the selection bias toward
symptomatic patients. Thus, an accurate and reliable
prediction of chronicity in the individual patient remains
an elusive goal, and until now predictors of chronicity
across the whole spectrum of patients with acute hepatitis
C have not been validated.
Our analysis shows that delaying therapy 2 months after
the onset of the disease does not affect the efficacy of
treatment. Therefore, from a practical point of view, we
suggest that patients be treated 60 days from the onset of
symptoms. This strategy avoids the unnecessary treatment
of affected patients who would spontaneously recover.
The results of this meta-analysis are subject to some
limitations. The included studies did not clearly define how
the enrolled patients were selected. Moreover, no study
reported whether patients were consecutively enrolled or
how many potentially eligible subjects did not enter the trials.
The available evidence support standard interferon
monotherapy as treatment for acute hepatitis C. Daily
induction dose during the 1st month is the best dose option,
and delaying therapy by 8–12 weeks after the onset of
disease does not compromise the response to treatment.
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